+

WO2003039439A3 - Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel - Google Patents

Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel Download PDF

Info

Publication number
WO2003039439A3
WO2003039439A3 PCT/DE2002/004216 DE0204216W WO03039439A3 WO 2003039439 A3 WO2003039439 A3 WO 2003039439A3 DE 0204216 W DE0204216 W DE 0204216W WO 03039439 A3 WO03039439 A3 WO 03039439A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
pyrazolopyrimidinones
hypertension
compounds
drugs containing
Prior art date
Application number
PCT/DE2002/004216
Other languages
English (en)
French (fr)
Other versions
WO2003039439A2 (de
Inventor
Rudolf-Giesbert Alken
Original Assignee
Bdd Group Holding Ag
Rudolf-Giesbert Alken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bdd Group Holding Ag, Rudolf-Giesbert Alken filed Critical Bdd Group Holding Ag
Priority to EP02779219A priority Critical patent/EP1444234A2/de
Priority to HU0401721A priority patent/HUP0401721A3/hu
Priority to IL16179002A priority patent/IL161790A0/xx
Priority to CA002470271A priority patent/CA2470271A1/en
Priority to JP2003541731A priority patent/JP2005509646A/ja
Priority to US10/494,914 priority patent/US20050069276A1/en
Priority to NZ533385A priority patent/NZ533385A/en
Publication of WO2003039439A2 publication Critical patent/WO2003039439A2/de
Publication of WO2003039439A3 publication Critical patent/WO2003039439A3/de
Priority to IS7246A priority patent/IS7246A/is
Priority to NO20042337A priority patent/NO20042337L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die Erfindung betrifft deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel. Weiterhin betrifft die Erfindung die Verwendung deuterierter Pyrazolopyrimidinone zur Hemmung der Thrombozyten-Adhäsion und -Aggregation, zur Langzeitsteigerung der Gedächtnisleistung und Lernfähigkeit sowie zur Behandlung von Herz- und Kreislauferkrankungen, Hypertonie, pulmonaler Hypertonie, erektiler Dysfunktion und obstruktiven Atemwegserkrankungen wie z.B. Asthma bronchiale. Ausserdem offenbart die Erfindung pharmazeutische Zusammensetzungen deuterierter Pyrazolopyrimidinone sowie deren physiologisch verträglicher Salze zur Hemmung der Thrombozyten-Adhäsion und -Aggregation, zur Langzeitsteigerung der Gedächtnisleistung und Lernfähigkeit sowie zur Behandlung von Herz- und Kreislauferkrankungen, Hypertonie, pulmonaler Hypertonie, erektiler Dysfunktion und obstruktiven Atemwegserkrankungen wie z.B. Asthma bronchiale neben pharmazeutisch verträglichen Hilfs- und/oder Zusatzstoffen.
PCT/DE2002/004216 2001-11-07 2002-11-07 Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel WO2003039439A2 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP02779219A EP1444234A2 (de) 2001-11-07 2002-11-07 Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel
HU0401721A HUP0401721A3 (en) 2001-11-07 2002-11-07 Deuterated pyrazolopyrimidinones, their use and drugs containing said compounds
IL16179002A IL161790A0 (en) 2001-11-07 2002-11-07 Deuterated pyrazolopyrimidinones and drugs containing said compounds
CA002470271A CA2470271A1 (en) 2001-11-07 2002-11-07 Deuterated pyrazolopyrimidinones and drugs containing said compounds
JP2003541731A JP2005509646A (ja) 2001-11-07 2002-11-07 重水素化されたピラゾロピリミジノン並びに前記化合物を含有する医薬品
US10/494,914 US20050069276A1 (en) 2001-11-07 2002-11-07 Deuterated pyrazolopyrimidinones and drugs containing said compounds
NZ533385A NZ533385A (en) 2001-11-07 2002-11-07 Deuterated pyrazolopyrimidinones and pharmaceuticals containing these compounds
IS7246A IS7246A (is) 2001-11-07 2004-04-30 Tvívetnis pýrasólópýrimidínon og lyf sem innihalda þessi efnasambönd
NO20042337A NO20042337L (no) 2001-11-07 2004-06-04 Deutererte pyrazolopyimidinoner sa vel som legemidler som inneholder disse forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10155018.9 2001-11-07
DE10155018A DE10155018A1 (de) 2001-11-07 2001-11-07 Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel

Publications (2)

Publication Number Publication Date
WO2003039439A2 WO2003039439A2 (de) 2003-05-15
WO2003039439A3 true WO2003039439A3 (de) 2003-10-16

Family

ID=7705148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/004216 WO2003039439A2 (de) 2001-11-07 2002-11-07 Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel

Country Status (16)

Country Link
US (1) US20050069276A1 (de)
EP (1) EP1444234A2 (de)
JP (1) JP2005509646A (de)
KR (1) KR20050044381A (de)
CN (1) CN1606557A (de)
CA (1) CA2470271A1 (de)
CZ (1) CZ2004639A3 (de)
DE (1) DE10155018A1 (de)
HU (1) HUP0401721A3 (de)
IL (1) IL161790A0 (de)
IS (1) IS7246A (de)
NO (1) NO20042337L (de)
NZ (1) NZ533385A (de)
PL (1) PL369654A1 (de)
RU (1) RU2004117157A (de)
WO (1) WO2003039439A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
CN102584592B (zh) * 2011-12-28 2014-10-15 李进 一种氘代的拟除虫菊酯化合物及其制备方法和应用
MX2015001246A (es) * 2012-07-30 2015-04-10 Concert Pharmaceuticals Inc Ibrutinib deuterado.
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
US20230348470A1 (en) * 2020-05-20 2023-11-02 Augusta University Research Institute, Inc. Gut-targeted phosphodiesterase inhibitors
CN116444496B (zh) * 2023-06-16 2023-11-24 药康众拓(北京)医药科技有限公司 一种嘧啶联氘代吡唑类化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (de) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidone als Wirkstoffe gegen Angina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (de) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidone als Wirkstoffe gegen Angina

Also Published As

Publication number Publication date
PL369654A1 (en) 2005-05-02
US20050069276A1 (en) 2005-03-31
CA2470271A1 (en) 2003-05-15
KR20050044381A (ko) 2005-05-12
HUP0401721A3 (en) 2005-11-28
WO2003039439A2 (de) 2003-05-15
CZ2004639A3 (cs) 2004-09-15
JP2005509646A (ja) 2005-04-14
RU2004117157A (ru) 2006-01-10
CN1606557A (zh) 2005-04-13
EP1444234A2 (de) 2004-08-11
IS7246A (is) 2004-04-30
IL161790A0 (en) 2005-11-20
HUP0401721A2 (hu) 2005-08-29
DE10155018A1 (de) 2003-07-10
NZ533385A (en) 2006-02-24
NO20042337L (no) 2004-06-04

Similar Documents

Publication Publication Date Title
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
WO2002066480A3 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
WO2003024433A3 (en) Compositions for treatment of common cold, comprising ipratropium and xylometazoline
TNSN05186A1 (en) Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
JP2009518415A5 (de)
JP2006508953A5 (de)
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
EP4442321A3 (de) Methoden zur behandlung von sjögren-syndrom mit einem hemmer von bruton-kinase
WO2003039439A3 (de) Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel
SG152257A1 (en) Topical preparation containing ambroxol
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2008115167A (ja) トラネキサム酸を含有する気道杯細胞過形成抑制剤
WO2005041922A3 (en) Composition
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2006020244A3 (en) Compositions and methods related to heart failure
BE2016C017I2 (de)
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 161790

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003541731

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047007039

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2004-639

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002779219

Country of ref document: EP

Ref document number: 325/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 533385

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002342566

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2470271

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20028254635

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002779219

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2004-639

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 10494914

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 533385

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002779219

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载